Premium
Open‐Label Trial of Cinnarizine in Migraine Prophylaxis
Author(s) -
Togha Mansooreh,
Ashrafian Hossein,
Tajik Parvin
Publication year - 2006
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.2006.00381.x
Subject(s) - cinnarizine , migraine , medicine , open label , anesthesia , migraine disorders , clinical trial
Objective.—To assess the effectiveness and safety of cinnarizine as a migraine‐preventive therapy. Methods.—Sixty patients with more than 2 migraine headache attacks during a 4‐week baseline entered the study and received a 25‐mg tablet cinnarizine twice daily for the first 3 days and then 3 times daily. They were assessed on weeks 2, 6, 10, and 14. Reduction from baseline in 4‐week migraine headache rate was the primary efficacy variable. Reduction in migraine attacks duration and severity was also evaluated. Results.—The mean reduction in 4‐week migraine headache rate was 4.6 ± 2.2 from the baseline of 6.2 ± 2.2 after 14 weeks of treatment, which was statistically significant ( P < 0.001). Percent reduction in 4‐week migraine frequency was 35% after 2 weeks, 74% after 6 weeks, 74% after 10 weeks, and 75% after 14 weeks of treatment. Significant reduction in attack duration ( P < 0.001) and severity ( P < 0.001) was also noted. No serious adverse events were observed in this series of patient. Conclusion.—Cinnarizine is an efficacious and well‐tolerated prophylactic antimigraine medication, which has early onset effectiveness.